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AclassofAg(I)N-heterocycliccarbenesilvercomplexes,1–3,derivedfrom4,5-dichloro-1H-imidazolehasbeenevaluatedfortheir
anticancer activity against the human cancer cell lines OVCAR-3 (ovarian), MB157 (breast), and Hela (cervical). Silver complexes
1–3 are active against the ovarian and breast cancer cell lines. A preliminary in vivo study shows 1 to be active against ovarian
cancer in mice. The results obtained in these studies warrant further investigation of these compounds in vivo.
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1. INTRODUCTION
Research eﬀorts into the development of new chemother-
apeutic anticancer agents play an important role in the
future treatment of cancer. The divergence from platinum-
based agents is becoming a point of emphasis with the
goal being to ﬁnd drugs that are as eﬀective as platinum
without the severity of side eﬀects. Metallocene dichlorides
and dirhodium carboxylates have shown anticancer activity,
however neither class of compounds has demonstrated
suﬃcient eﬀectiveness to pursue past phase II clinical trials
[1, 2].
Recently, silver complexes have been reported to have
anticancer activity in vitro. Egan has reported that silver
complexes of coumarin derivatives possess anticancer activ-
ity against certain types of cancer [3]. Zhu has reported that
silver carboxylate dimers possess anticancer activity against
human carcinoma cells [4]. McKeage has shown phosphine
complexes of silver to be active anticancer agents, even
against cisplatin resistant cell lines [5].
Research into using silver is essential as toxicity is
believed to be quite low. In fact, silver has been detected
in 29 human tissues in trace amounts; however, there is
no known physiological function for silver. In vitro studies
have shown that silver salts do have an eﬀect on dermal
ﬁbroblasts; however, the eﬀect usually does not lead to cell
death [6]. Also, silver is being used in vivo to coat foreign
materials. Artiﬁcial heart valves, along with cardiac and
urinary catheters, are being coated with silver in medical
applicationstoreduceorpreventtheinfectionrateofvarious
microbes [7–10]. The problem with ingestion of silver is
a permanent discoloration of the skin known as argyria.
However, argyria is not believed to be harmful to the body
physically and it takes an excessive consumption of silver to
develop this condition [11].
Based on the previously discussed reports of the anti-
tumor activity of silver and our expertise in silver N-
Heterocyclic carbene complexes [12–15], along with other
reported N-Heterocyclic carbene complexes possessing anti-
cancer activity [16–18], we have begun to examine the
anticancer activity of Ag(I) complexes of N-Heterocyclic
carbenes. Herein, we report the anticancer activity of three
Ag(I)-N-Heterocyclic carbene complexes derived from 4,5-
dichloro-1H-imidazole. These silver complexes appear to be
stable to light and water making them viable candidates for
use as chemotherapeutic agents.
2. RESULTS AND DISCUSSION
The imidazolium salts and their silver acetate complexes
1, 2,a n d3 were synthesized similarly to procedures in a
previously published procedure from our group [19]. These2 Metal-Based Drugs
Table 1: IC50 concentrations of silver drugs.
OVCAR-3(a) MB157(a) Hela(a)
Cisplatin 12 25 25
AgNO3 35 5 50
AgOAc 20 12 NA
1 35 8 >200
2 30 20 >200
3 20 10 >200
(a)IC50 concentrationsarereportedinmicromolar.NA=notachievabledue
to solubility of AgOAc.
silver complexes have been shown to be very stable and can
be synthesized eﬃciently [19].
Silver complexes of type 1, 2,a n d3 have been chosen
overtheuseofsilversaltsbecauseoftheirstability.Theuseof
silver salts in vivo is not practical because the free silver ions
will form complexes with salts in the bloodstream.
The MTT assay was run against the cancer cell lines
OVCAR-3 (ovarian), MB157 (breast), and Hela (cervical)
to determine the in vitro anticancer eﬃcacy of 1–3, the
imidazolium salt precursors, silver nitrate, and silver acetate
relative to that of Cisplatin. Cancer cells were plated at
cell densities of 5000 cells per well in 96-well plates and
allowed to incubate overnight. The following day, the test
compounds were dissolved in DMSO [20] and diluted into
the respective cell culture media to the desired micromolar
concentrations. The media in the wells was replaced with
freshmediacontainingtestcompoundorDMSOforcontrol,
and the cells were incubated for 72 hours. Following this test,
period MTT protocol was followed by adding 10μLo fM T T
in PBS to each well, and the plates were incubated for four
hours. In viable, metabolically active cells, MTT is reduced
in the mitochondria by the enzyme succinate dehydrogenase
forming insoluble bluish purple formazan crystals. These
formazan crystals are then resolublized by addition of 100μL
of SDS in dilute HCl. The optical density of each well is then
read at 570nm. The imidazolium salts showed no activity
against the cancer cell lines, while the silver complexes
1–3 were very eﬃcacious against the ovarian and breast
cancer cell lines, while showing very minimal eﬀect on the
cervical cancer cell line. The IC50 concentrations for active
compounds, where IC50 stands for the concentration that
causes a 50% reduction in cell viability, are reported in
Table 1.
To determine the eﬀect of silver complexes 1–3 and
Cisplatin on the morphology of the OVCAR-3 and MB157
cells in culture, phase contrast pictures were taken of tested
cell culture. The cells were dyed with Hoesch for clarity
purposesonly.Cellswereplatedin24-wellplatesandallowed
to grow to conﬂuency. Test compounds were dissolved in
DMSO and diluted into the respective cell culture media
to the desired micromolar concentrations. The media in
the wells was replaced with fresh media containing test
compound or DMSO for control. Cells were incubated with
test compounds at 50μM for 36 hours. Selected results are
shown as pictures in Figures 2–7.
The above described pictures show that these silver com-
pounds have signiﬁcant eﬀect on cell viability. These results
qualitatively show that both the OVCAR-3 and MB157 cell
lines did not survive the exposure to 1–3 at 50μM. All of
the silver complexes demonstrated superior eﬀectiveness as
compared to Cisplatin at the same concentration.
To quantify the eﬃcacy of the silver complexes, a
live/dead cell assay was performed. Selected ﬂuorescence
images are shown in Figures 8–13. Cells were plated in
24-well plates and allowed to grow to conﬂuency. Test
compounds were dissolved in DMSO and diluted into the
respective cell culture media to the desired micromolar
concentrations. The media in the wells was replaced with
freshmediacontainingtestcompoundorDMSOforcontrol.
Cells were incubated with test compounds at 50μMf o r
36hours. Live cells ﬂuoresced red due to their metabolic
activity that converted the stain C12-resazurin into ﬂuores-
cent C12-resoruﬁn. Dead cells accumulated the Sytox green
stain since their cell membranes had been compromised,
resulting in green ﬂuorescence. The silver complexes 1–3
produced signiﬁcantly higher death among the OVCAR-3
cell compared to Cisplatin and control OVCAR-3 cells (P<
.0001). The viabilities of OVCAR-3 cells exposed to 1–3
were 11%, 0%, and 0%, respectively. Meanwhile, OVCAR-
3 cells exposed to Cisplatin resulted in 78% viability, which
was not signiﬁcantly diﬀerent than the control cells 93%
viability (P = .5579). All silver complexes and Cisplatin
produced signiﬁcant death among MB157 breast cancer
cells. The live/dead assay revealed 10% cell viability for
MB157 cells exposed to Cisplatin, which was signiﬁcantly
diﬀerent than the 92% viability for the MB157 control cells
(P<. 0001). Based on the live/dead assay, 1–3, showed
signiﬁcantly superior cell lysing capabilities with ovarian
cancer compared to Cisplatin. These silver complexes also
were shown to completely kill the breast cancer cell line
MB157. Our ﬁndings suggest silver complexes of this type
may be excellent candidates for therapeutic drugs for certain
types of cancer.
The cell viability percentages were tallied from the
live/dead assay data and shown in Figure 14. The data from
microscopy and live/dead assay coincides with the MTT
assay except for the Cisplatin data. This discrepancy can be
attributed to the fact that Cisplatin takes longer incubation
periodstobefullyeﬀectiveagainstthecellslines.IntheMTT,
assay cells had to be incubated for 72hours to see maximum
eﬃcacy, here the incubation time was only 36hours.
Due to the activity of these silver complexes, in vitro,
a preliminary in vivo study was run to determine if 1 was
activeagainstanovariancancerxenograftmodel.Tenmillion
OVCAR-3 cells were injected subcutaneously into the back
of female athymic nude mice. Upon visible tumor growth,
approximately six weeks, silver complex 1 was injected
subcutaneously at the tumor site every third day for ten
days. Each dose consisted of 333mg/kg of 1 for a total of
1000mg/kg over the ten day period. The high dose was
chosen because a parallel study was being run, where IP
injections were given at a dose of 100mg/kg per day and it
seemed relevant to give the same total dose over this ten-day































Figure 1: Imidazolium salts precursors of (a) 1,( b )2,( c )3.
100μm
Figure 2: OVCAR-3 control.
compound absorbed more slowly in the subcutaneous study.
The mice were then necropsied to determine what eﬀect 1
hadonthetumors,aswellas,ontheinternalorgans.Selected
pictures of the tumors, along with the internal organs, are
shown in Figures 15–17. According to pathological results, 1
caused major cell death of the tumors, however, showed no
ill-eﬀects to the major organs of the mice.
3. CONCLUSION
In conclusion, we have shown a class of Ag(I) N-Heterocyclic
carbenes to possess anticancer activity, in vitro, against
ovarian (OVCAR-3) and breast (MB157) cancer; however,
these silver complexes have little eﬀect on cervical (Hela)
cancer.Eachcompound,1–3,seemstobemoreactiveagainst
the breast cancer cell line MB157 with IC50’s of around
10μM.
Preliminary in vivo studies show that 1 is active against
an ovarian cancer xenograft model by subcutaneous injec-
100μm
Figure 3: OVCAR-3 incubated with Cisplatin.
tion. Further in vivo studies are underway to determine the
eﬀect of 1 on the ovarian cancer xenograft model, where
the mode of delivery is through intraperitoneal injection.
These ﬁndings indicate that N-Heterocyclic carbene silver
complexes may be useful in cancer chemotherapy depending
on the type of cancer.
4. EXPERIMENTAL
4.1. General
4,5-dichloro-1H-imidazole was purchased from TCI
(Wellesly Hills, Ma, USA). 1-bromohexane was
purchased from Aldrich (Louis Street, Mo ,USA). 2-
bromomethylnaphthalene was purchased from Alfa (Ward
Hill, Ma, USA). All chemicals were used without further
puriﬁcation. All mass spectrometry was performed at
CCIC at The Ohio State University. 1Ha n d13CN M R
spectra were obtained on a Varian 300MHz or Varian4 Metal-Based Drugs
100μm
Figure 4: OVCAR-3 incubated with 1.
100μm
Figure 5: MB157 control.
500MHz instrument. All elemental analyses were performed
at the University of Illinois at Urbana-Champaign.




chased from ATCC (Manassas, Va, USA). The OVCAR-3 cell
line was grown in RPMI 1640 media with 2mM L-glutamine
and modiﬁed to contain 10mM HEPES, 1mM sodium
pyruvate, 4.5g/L glucose, and 1.5g/L sodium bicarbonate
and was supplemented with .01mg/mL bovine insulin and
20% fetal bovine serum. The cells were grown at 37
◦Cw i t h
5% CO2 and passed every 2-3 days. The MB157 cell line
was grown in DMEM with 4mM L-glutamine modiﬁed to
contain 4.5g/L glucose and 1.5g/L sodium bicarbonate and
supplemented with 10% fetal bovine serum. The cells were
grown at 37
◦Cw i t h5 %C O 2 and passed every 2-3 days. The
human cancer cell line Hela S3 was donated by Dr. Yang Yun
of the Biomedical Engineering department at the University
of Akron. The Hela cell line was grown in DMEM/F-12K
100μm
Figure 6: MB157 incubated with Cisplatin.
100μm
Figure 7: MB157 incubated with 1.
media supplemented with 1% antibiotic/antimicotic and
10% fetal bovine serum. The cells were grown at 37
◦Cw i t h
5% CO2 a n dp a s s e do n c eaw e e k .
4.3. MTTassay
The MTT assay was purchased from Molecular Probes (Part
o fI n v i t r o g e n ) .T h er e s p e c t i v ec e l ll i n e sw e r eg r o w nt o
conﬂuency and plated in 96-well plates at 5000 cells per well
in triplicate and allowed to incubate overnight. Compounds
1, 2, 3, the imidazolium salts precursors, Cisplatin, silver
acetate, and silver nitrate were dissolved in DMSO to a
concentration of 0.1M and diluted into cell culture media
to the desired testing concentrations. Media in each well was
removed and replaced with the fresh media containing test
compounds. The test compounds were allowed to incubate
for 24, 48, or 72hours after which the MTT protocol was
followed. A stock solution of MTT was prepared by adding
1mL of PBS to the preweighed vial containing MTT. 10μL
of this stock solution were added to each well and allowed
to incubate for 4hours. A stock solution of sodium dodecyl
sulfate was prepared by adding 10mL of 0.01M HCl toDoug A. Medvetz et al. 5
200μm
Figure 8: OVCAR-3 control.
200μm
Figure 9: OVCAR-3 incubated with Cisplatin.
the preweighed SDS vial. Following the 4 hour incubation
period, 100μL of the SDS:HCl solution were added and
incubated overnight. The optical density was read at 570nm
on Molecular Devices Spectramax M2 plate reader.
4.4. Microscopy
Cells were plated at 50000 cells per well in 24-well plates and
the culture was allowed to grow to conﬂuency. Compounds
1, 2, 3, and Cisplatin were dissolved in DMSO to a
concentration of 0.1M and diluted into cell culture media
to the desired testing concentrations. Media in each well
was removed and replaced with the fresh media containing
test compounds. The test compounds were incubated for
36hours. Afterwards, cells were rinsed with PBS and ﬁxed
for 10 minutes with freshly prepared 0.5% formaldehyde
solution. After ﬁxation, cells were rinsed and permeabilized
with 0.2% Triton X solution for 10 minutes. Hoechst
nuclear dye was prepared according to the manufacturer’s
recommendations and carefully applied to the cells. After
30 minutes of incubation, cells were rinsed three times with
PBS and visualized with ﬂuorescence microscopy. All images
were captured using AxioVision 200 by Zeiss with a 10x
200μm
Figure 10: OVCAR-3 incubated with 1.
200μm
Figure 11: MB157 control.
Plan Neoﬂuor Zeiss objective and a high-resolution CCD
HRm camera. The ﬂourescent and phase contrast images
were colocalized using the AxioVision software version 4.6.
4.5. Live/deadassay
The live/dead assay was purchased from Invitrogen (Carls-
bad, Ca, USA). Cells were plated in 24-well plates. Com-
pounds 1, 2, 3, and Cisplatin were dissolved in DMSO to a
concentration of 0.1M and diluted into cell culture media
to the desired testing concentrations. Media in each well was
removed and replaced with the fresh media containing test
compounds. The test compounds were allowed to incubate
for 36hours. The live/dead stains were then prepared by
dissolving 40μgo fC 12-Resazurin in 100μLo fD M S Oa sa
1mMstocksolution.A50μMC 12-Resazurin solution was
then made up by diluting 2.5μL of the stock solution into
47.5μL of DMSO. The Sytox green solution was prepared by
diluting 5μLo fa1 0μMs t o c ks o l u t i o ni n4 5μLo fD M S O .
The staining solution was prepared by diluting 48μLo f
50μMC 12-Resazurin and 48μL of Sytox green stain into
4.704mL of 1X PBS for ﬁnal concentrations of 500nM. The
cell media was then removed from culture, and the cells were6 Metal-Based Drugs
200μm
Figure 12: MB157 incubated with Cisplatin.
200μm
Figure 13: MB157 incubated with 1.
washed with 1X PBS. Cells were then covered with 200μLo f
live/dead staining solution and incubated for 15 minutes at
room temperature protected from light. Lastly, the cells were
visualized using a ﬂuorescent microscope. Three random
imagesweretakenperwell,andthechannelswerecombined,
and the images were processed using Axiovision software
as previously described. Cell viabilities were found to be
signiﬁcant using Tukey’s multiple comparison among means
(α = 0.05).
4.6. Ovariancancerxenograftmodel
Three-week-old female athymic nude mice were purchased
from Harlan (Indianapolis, In, USA) and housed for one
week prior to the experiment. Ten million cells were injected
subcutaneously into the back of three animals, right below
the ear. The animals were monitored and the weights were
recorded 2-3 times per week until the tumors grew to
be visible (macroscopic tumors grew in about six weeks).
The next day, and every third day following for ten days,
the animals were injected with a dose of 333mg/kg of
compound 1 subcutaneously at the tumor site for a total of






































Figure 14: Percent viability of OVCAR-3 and MB157 after testing
with cisplatin (Cis), silver acetate, (AgOAc), and silver nitrate
(AgNO3),1,2,and3.Thepercentagesarebasedoncellcountsfrom
the live/dead assay data after cells were tested for 36 hours. Cells
were incubated with test compounds at 50μM.
Figure 15: Necrotic tumor mass.
Figure 16: Normal tumor mass.Doug A. Medvetz et al. 7
Figure 17: View of the internal organs.
1000mg/kg. After ten days, the animals were sacriﬁced, and
a full necropsy was performed. The brain, liver, lungs, heart,
kidneys, spleen, and tumors were sent for pathology report.
Synthetic, NMR, and crystallographic data for the imida-
zolium salts and their silver acetate structures are available
as Supplementary Material at doi:10.1155/2008/384010.
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